Molecular Formula | C23H17FN6O2 |
Molar Mass | 428.42 |
Density | 1.37±0.1 g/cm3(Predicted) |
Boling Point | 612.3±65.0 °C(Predicted) |
Solubility | 10 mM in DMSO |
pKa | -0.34±0.12(Predicted) |
Storage Condition | -20℃ |
In vivo study | TAK-063 has high brain permeability in mice. Oral administration of TAK-063 at a dose of 0.3 mg/kg in mice increased cAMP and cGMP levels. It has a potent inhibitory effect on the rapid movement induced by PCP. TAK-063 is currently in the clinical research stage to study its effect on the treatment of schizophrenia. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.334 ml | 11.671 ml | 23.342 ml |
5 mM | 0.467 ml | 2.334 ml | 4.668 ml |
10 mM | 0.233 ml | 1.167 ml | 2.334 ml |
5 mM | 0.047 ml | 0.233 ml | 0.467 ml |